Revvity, Inc.
HealthcareNYSE:RVTY · New York Stock Exchange
-$1.86 today
Vol 0.93M · Avg 1.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
3.3%
avg 8.1%
ROIC
2.8%
avg 5.8%
ROA
2.0%
avg 3.9%
Analysis
ROE is currently the strongest return metric at 3.3% versus its period average of 8.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Prahlad R. Singh | Chief Executive Officer, President & Director | $3.56M | — | 61 | $22,676.00 | 0.02% |
Joel S. Goldberg | Senior Vice President of Administration, General Counsel & Secretary | $1.25M | — | 57 | $41,514.00 | 0.04% |
Maxwell Krakowiak | Senior Vice President & Chief Financial Officer | $1.18M | — | 36 | $17,314.00 | 0.02% |
Miriame Victor | Senior Vice President & Chief Commercial Officer | $1.04M | — | 45 | $19,984.00 | 0.02% |
Tajinder Vohra | Senior Vice President of Global Operations | $1.03M | — | 60 | $13,965.00 | 0.01% |
Anita Gonzales | Chief Accounting Officer, Vice President & Controller | — | — | 50 | $7,319.00 | <0.01% |
Madhuri FACMG | Senior Vice President & Chief Scientific Officer | — | — | — | — | — |
Magali Four | Senior Vice President & Chief People and Culture Officer | — | — | — | — | — |
Bryan A. Kipp | Senior Vice President of Technology & Licensing | — | — | — | — | — |
Stephen Barr Willoughby | Senior Vice President of Investor Relations & Head of ESG | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$4.72M
Net Sentiment
$4.72M
Net selling
Most Active
Singh Prahlad R.
5 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $4.72M over the last 12 months. That adds up to net selling of $4.72M. Singh Prahlad R. was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +46.5% | +9.4% (15yr)1 analysts |
| Revenue | N/A | N/A | -0.2% | +3.5% (15yr)3 analysts |
| Net Income | N/A | N/A | +45.9% | +9.4% (15yr)3 analysts |
| EBIT | N/A | N/A | +9.9% | +6.3% (15yr)3 analysts |
Analysis
Recent growth has been strongest in EPS at +46.5% over three years. Forward estimates point to EPS at +9.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Guardant Health, Inc.
NASDAQ:GH
$17.45B
Solventum Corporation
NYSE:SOLV
$13.66B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.07B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.03B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.73B
Qiagen N.V.
NYSE:QGEN
$7.64B
Hims & Hers Health, Inc.
NYSE:HIMS
$5.98B
Who manages RVTY?
Revvity, Inc. (RVTY) lists 10 active executives. The top listed executive is Anita Gonzales, Chief Accounting Officer, Vice President & Controller.
Are RVTY insiders buying or selling?
Recent insider activity shows net buying of $36.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.